Process of preparation of olanzapine form I

• US 7,297,789 B2
• Filed: 05/30/2003
• Issued: 11/20/2007
• Est. Priority Date: 05/31/2002
• Status: Expired due to Fees

• Current Assignee: Sandoz Ag (Novartis Ag)
• Original Assignee: Sandoz Inc. (Novartis Ag)
• Inventors: Patel, Mahendra R., Patel, Pramod B., Ray, Anup K., Patel, Hiren V.
• Primary Examiner(s): Coleman; Brenda
• Application Number:
  US10/449,643
• Publication Number:
  US 20040048854A1
• Time in Patent Office: 1,635 Days
• Field of Search: 514/220, 540/557
• US Class Current: 540/557
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: C07D 495/04 Ortho-condensed systems

Abstract

A process for the preparation of polymorph Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine, or olanzapine.

Claims

1. A process for preparing polymorphic olanzapine Form I comprising:

a) reacting 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine HCI and 1-methylpiperazine in an aprotic high boiling solvent or mixtures thereof at a temperature of between about 90°

C. to 130°

C.;

b) purifying the product of step a) in an acidic medium;

c) basifying the product of step b) to a pH of between 7.5-9; and

d) extracting the product of step c) using a low boiling organic solvent.

2. The process of claim 1 wherein the temperature of step (a) ranges from about 115°

C. to about 120°

C.

3. The process of claim 1 wherein the temperature of step (a) is about 110°

C.

4. The process of claim 1 wherein the aprotic high boiling solvent is selected from the group consisting of dimethyl sulfoxide, dimethylformamide, a mixture of dimethyl sulfoxide and toluene, and a mixture of dimethylformamide and toluene.

5. The process of claim 1 wherein the low boiling organic solvent is selected from the group consisting of diethylether, dichloromethane, dichloroethane, chloroform, ethyl acetate, other low polar ketonic solvents, and mixtures thereof.

6. The process of claim 1 wherein the low boiling organic solvent is dichloromethane.

7. The process of claim 1 wherein the acidic medium is an organic acid.

8. The process of claim 7 wherein the organic acid is acetic acid.

9. The process of claim 1 wherein the product of step b) is basified by adding sodium hydroxide.

10. The process of claim 1 wherein the product of step b) is basified to a pH ranging from about 7.5 to about 8.5.

11. The process of claim 1 wherein the product of step b) is basified to pH ranging from about 7.5 to about 8.

12. The process of claim 1 further comprising crystallization of olanzapine Form I by the steps of

e) adding a basic solvent;

and

f) seeding the solution of step e) with olanzapine Form I at a temperature ranging from about 0°

C. to about 30°

C.

13. The process of claim 12 further comprising:

g) adding toluene in step d), removing the low boiling organic solvent by evaporation, and seeding the toluene solution with pure olanzapine Form I at temperature ranging from about 0°

C. to about 30°

C., wherein the low boiling organic solvent is selected from the group consisting of diethylether, dichloromethane, dichloroethane, chloroform, ethyl acetate, other low polar ketonic solvents, and mixtures thereof.

14. A process of claim 12 wherein the basic solvent is a combination of an inorganic base and a high boiling solvent.

15. A process of claim 12 wherein the basic solvent is a mixture of toluene and methanolic sodium hydroxide.

16. A process of claim 12 further comprising a crystallization to obtain olanzapine Form I of at least 99.8% HPLC purity.

18. The process of claim 1 further comprising the steps of:

e) adding a basic solvent to provide a solution; and

f) crystallizing olanzapine Form I from the solution obtained in step e) at a temperature ranging from about 0°

C. to about 30°

C.

17. A method for preparing olanzapine Form I comprising mixing 4-amino-2-methyl-10H-thieno [2,3-b][1,5]benzodiazepine hydrochloride with a mixture of 1-methylpiperazine, dimethylsulfoxide, toluene, and methanolic sodium hydroxide.